28A-1100705
PCT, TW filing
Peptidoglycan (PGN) fragments have been found to stimulate innate immune responses through recognition with the human intracellular nucleotide-binding oligomerization domain-containing protein 1 (NOD1), to induce the activation of the NF-κB pathway and the production of cytokines. A series of innovative enantiopure tripeptide-based analogs were designed with a specific scaffold, l-Ala--d-Glu-(2R,6S)-DAHA. A novel bifunctional Ionic liquid supported synthesis were used to produce these analogs. Great stimulating potency of the enantiopure tripeptide-based analogs to NOD1 receptor were shown, compared with current known modulators. Potentially, those newly designed tripeptide-based NOD1 agonists can be applied as innate immune modulators, vaccine adjuvant, and the treatments of autoimmune disease, such as ulcerative colitis, rheumatoid arthritis, allergic rhinitis, atherosclerosis, metabolic syndrome, and gestational diabetes.
- A novel bifunctional ionic liquid (IL)-matrix supported synthesis to accelerate process
- The new enantiopure tri-peptide-based library synthesis inspired from bacterial cell wall natural products
- Discovery of new and potent NOD1 agonists with the specific hydroxymethyl moiety, increasing the potency to stimulate NF-κB activity
- New scaffolds and new molecules
- Innate immune modulators through human NOD1 receptor
- Potential vaccine adjuvants
- Potential immunotherapeutic agents for various diseases
Cheng, Wei-Chieh
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Novel molecules as modulators of NOD1 receptor signaling